Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy

Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients.

Issam Makhoul
Valentina K Todorova
Eric R Siegel
Stephen W Erickson
Ishwori Dhakal
Vinay R Raj
Jeannette Y Lee
Mohammed S Orloff
Robert J Griffin
Ronda S Henry-Tillman
Suzanne Klimberg
Laura F Hutchins
Susan A Kadlubar

January 2017

We previously reported improved pathologic complete response (pCR) in a prospective phase II study u...

Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100

Schneider, B. P.
Li, L.
Shen, F.
Miller, K. D.
Radovich, M.
O'Neill, A.
Gray, R. J.
Lane, D.
Flockhart, D. A.
Jiang, G.
Wang, Z.
Lai, D.
Koller, D.
Pratt, J. H.
Dang, C. T.
Northfelt, D.
Perez, E. A.
Shenkier, T.
Cobleigh, M.
Smith, M. L.
Railey, E.
Partridge, A.
Gralow, J.
Sparano, J.
Davidson, N. E.
Foroud, T.
Sledge, G. W.

September 2014

Background: Bevacizumab has broad anti-tumour activity, but substantial risk of hypertension. No rel...

VEGF GENE POLYMORPHISMS IN THE PREDICTION OF BENEFIT FROM FIRST-LINE FOLFIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)

Loupakis, F
Ruzzo, Annamaria
Salvatore, L
Canestrari, E
Cremolini, C
Masi, G
Schirripa, M
Spoto, C
Galluccio, N
Vincenzi, B
Santini, D
Bencardino, K
Ricci, V
Catalano, V
Manzoni, M
Danova, M
Tonini, G
Magnani, Mauro
Falcone, A
Graziano, F.

January 2009

Introduction: Addition of BV to first-line irinotecan plus 5FU improves PFS and OS of mCRC pts. Mea...

Genetic markers of bevacizumab-induced hypertension

Lambrechts, Diether
Moisse, Matthieu
Delmar, Paul
Miles, David W
Leighl, Natasha
Escudier, Bernard
Van Cutsem, Eric
Bansal, Aruna T
Carmeliet, Peter
Scherer, Stefan J
de Haas, Sanne
Pallaud, Celine

July 2014

There are currently no validated biomarkers predicting bevacizumab treatment outcome or toxicity. We...

Identification and functional study of a VEGFR-1 locus predicting bevacizumab treatment outcome

Claes, Bart

July 2012

Insights into the molecular genetics of cancer have fueled the development of so-called targeted th...

Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase 3 GeparQuinto study

Hein, Alexander
Lambrechts, Diether
von Minckwitz, Gunter
Häberle, Lothar
Eidtmann, Holger
Tesch, Hans
Untch, Michael
Hilfrich, Jörn
Schem, Christian
Rezai, Mahdi
Gerber, Bernd
Dan Costa, Serban
Blohmer, Jens-Uwe
Schwedler, Kathrin
Kittel, Kornelia
Fehm, Tanja
Kunz, Georg
Beckmann, Matthias W
Ekici, Arif B
Hanusch, Claus
Huober, Jens
Liedtke, Cornelia
Mau, Christine
Moisse, Matthieu
Müller, Volkmar
Nekljudova, Valentina
Peuteman, Gilian
Rack, Brigitte
Rübner, Matthias
Van Brussel, Thomas
Wang, Liewei
Weinshilboum, Richard M
Loibl, Sibylle
Fasching, Peter A

December 2015

Studies assessing the effect of bevacizumab (BEV) on breast cancer outcome have shown different effe...

Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial

de Rauglaudre, Bernadette
Sibertin-Blanc, Camille
Fabre, Aurelie J
Le Malicot, Karine
Bennouna, Jaafar
Ghiringhelli, François
Taïeb, Julien
Boige, Valérie
Bouché, Olivier
Chatellier, Thierry
Faroux, Roger
François, Eric
Jacquot, Stéphane
Genet, Dominique
Mulot, Claire
Olschwang, Sylviane
Seitz, Jean-François
Aparicio, Thomas
Dahan, Laetitia

January 2022

International audienceBackground: Several studies have reported the impact of single nucleotide poly...

Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.

Loupakis F
Cremolini C
Yang D
Salvatore L
Zhang W
Wakatsuki T
Bohanes P
Schirripa M
Benhaim L
Lonardi S
Antoniotti C
Aprile G
Graziano F
Ruzzo A
Lucchesi S
Ronzoni M
Tonini G
Falcone A
Lenz H.J.
DE VITA, Ferdinando

January 2013

PURPOSE: The potential impact of different SNPs of VEGF/VEGFR pathway on the clinical outcome of mC...

Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab

Formica, V
Palmirotta, R
Del Monte, G
Savonarola, A
Ludovici, G
De Marchis, ML
Grenga, I
Schirru, M
Guadagni, F
Roselli, M

February 2011

The aim of this study is to evaluate the influence of germline vascular endothelial growth factor (V...

Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study

Hein, Alexander
Lambrechts, Diether
von Minckwitz, Gunter
Haeberle, Lothar
Eidtmann, Holger
Tesch, Hans
Untch, Michael
Hilfrich, Joern
Schem, Christian
Rezai, Mahdi
Gerber, Bernd
Costa, Serban Dan
Blohmer, Jens-Uwe
Schwedler, Kathrin
Kittel, Kornelia
Fehm, Tanja
Kunz, Georg
Beckmann, Matthias W
Ekici, Arif B
Hanusch, Claus
Huober, Jens
Liedtke, Cornelia
Mau, Christine
Moisse, Matthieu
Mueller, Volkmar
Nekljudova, Valentina
Peuteman, Gilian
Rack, Brigitte
Rubner, Matthias
Van Brussel, Thomas
Wang, Liewei
Weinshilboum, Richard M
Loibl, Sibylle
Fasching, Peter A

December 2015

Studies assessing the effect of bevacizumab (BEV) on breast cancer (BC) outcome have shown different...

Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

LOUPAKIS F
RUZZO, ANNAMARIA
SALVATORE L
CREMOLINI C
MASI G
FRUMENTO P
SCHIRRIPA, M
CATALANO V
GALLUCCIO N
CANESTRARI E
VINCENZI B
SANTINI D
BENCARDINO K
RICCI V
MANZONI M
DANOVA M
TONINI G
MAGNANI, MAURO
FALCONE A
GRAZIANO F.

January 2011

Background: Molecular predictors of bevacizumab efficacy in colorectal cancer have not been identifi...

Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab

Fotios Loupakis (430779)
Chiara Cremolini (430780)
Dongyun Yang (430781)
Lisa Salvatore (430782)
Wu Zhang (220174)
Takeru Wakatsuki (430783)
Pierre Bohanes (430784)
Marta Schirripa (430785)
Leonor Benhaim (430786)
Sara Lonardi (430787)
Carlotta Antoniotti (430788)
Giuseppe Aprile (89417)
Francesco Graziano (430789)
Annamaria Ruzzo (430790)
Sara Lucchesi (430791)
Monica Ronzoni (430792)
Ferdinando De Vita (337845)
Giuseppe Tonini (222938)
Alfredo Falcone (121178)
Heinz-Josef Lenz (430793)

July 2013

<div>PurposeThe potential impact of different SNPs of VEGF/VEGFR pathway on the cli...

Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients.

Issam Makhoul
Valentina K Todorova
Eric R Siegel
Stephen W Erickson
Ishwori Dhakal
Vinay R Raj
Jeannette Y Lee
Mohammed S Orloff
Robert J Griffin
Ronda S Henry-Tillman
Suzanne Klimberg
Laura F Hutchins
Susan A Kadlubar

January 2017

We previously reported improved pathologic complete response (pCR) in a prospective phase II study u...

Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100

Schneider, B. P.
Li, L.
Shen, F.
Miller, K. D.
Radovich, M.
O'Neill, A.
Gray, R. J.
Lane, D.
Flockhart, D. A.
Jiang, G.
Wang, Z.
Lai, D.
Koller, D.
Pratt, J. H.
Dang, C. T.
Northfelt, D.
Perez, E. A.
Shenkier, T.
Cobleigh, M.
Smith, M. L.
Railey, E.
Partridge, A.
Gralow, J.
Sparano, J.
Davidson, N. E.
Foroud, T.
Sledge, G. W.

September 2014

Background: Bevacizumab has broad anti-tumour activity, but substantial risk of hypertension. No rel...

VEGF GENE POLYMORPHISMS IN THE PREDICTION OF BENEFIT FROM FIRST-LINE FOLFIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)

Loupakis, F
Ruzzo, Annamaria
Salvatore, L
Canestrari, E
Cremolini, C
Masi, G
Schirripa, M
Spoto, C
Galluccio, N
Vincenzi, B
Santini, D
Bencardino, K
Ricci, V
Catalano, V
Manzoni, M
Danova, M
Tonini, G
Magnani, Mauro
Falcone, A
Graziano, F.

January 2009

Introduction: Addition of BV to first-line irinotecan plus 5FU improves PFS and OS of mCRC pts. Mea...

Genetic markers of bevacizumab-induced hypertension

Lambrechts, Diether
Moisse, Matthieu
Delmar, Paul
Miles, David W
Leighl, Natasha
Escudier, Bernard
Van Cutsem, Eric
Bansal, Aruna T
Carmeliet, Peter
Scherer, Stefan J
de Haas, Sanne
Pallaud, Celine

July 2014

There are currently no validated biomarkers predicting bevacizumab treatment outcome or toxicity. We...

Identification and functional study of a VEGFR-1 locus predicting bevacizumab treatment outcome

Claes, Bart

July 2012

Insights into the molecular genetics of cancer have fueled the development of so-called targeted th...

Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase 3 GeparQuinto study

Hein, Alexander
Lambrechts, Diether
von Minckwitz, Gunter
Häberle, Lothar
Eidtmann, Holger
Tesch, Hans
Untch, Michael
Hilfrich, Jörn
Schem, Christian
Rezai, Mahdi
Gerber, Bernd
Dan Costa, Serban
Blohmer, Jens-Uwe
Schwedler, Kathrin
Kittel, Kornelia
Fehm, Tanja
Kunz, Georg
Beckmann, Matthias W
Ekici, Arif B
Hanusch, Claus
Huober, Jens
Liedtke, Cornelia
Mau, Christine
Moisse, Matthieu
Müller, Volkmar
Nekljudova, Valentina
Peuteman, Gilian
Rack, Brigitte
Rübner, Matthias
Van Brussel, Thomas
Wang, Liewei
Weinshilboum, Richard M
Loibl, Sibylle
Fasching, Peter A

December 2015

Studies assessing the effect of bevacizumab (BEV) on breast cancer outcome have shown different effe...

Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial

de Rauglaudre, Bernadette
Sibertin-Blanc, Camille
Fabre, Aurelie J
Le Malicot, Karine
Bennouna, Jaafar
Ghiringhelli, François
Taïeb, Julien
Boige, Valérie
Bouché, Olivier
Chatellier, Thierry
Faroux, Roger
François, Eric
Jacquot, Stéphane
Genet, Dominique
Mulot, Claire
Olschwang, Sylviane
Seitz, Jean-François
Aparicio, Thomas
Dahan, Laetitia

January 2022

International audienceBackground: Several studies have reported the impact of single nucleotide poly...

Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.

Loupakis F
Cremolini C
Yang D
Salvatore L
Zhang W
Wakatsuki T
Bohanes P
Schirripa M
Benhaim L
Lonardi S
Antoniotti C
Aprile G
Graziano F
Ruzzo A
Lucchesi S
Ronzoni M
Tonini G
Falcone A
Lenz H.J.
DE VITA, Ferdinando

January 2013

PURPOSE: The potential impact of different SNPs of VEGF/VEGFR pathway on the clinical outcome of mC...

Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab

Formica, V
Palmirotta, R
Del Monte, G
Savonarola, A
Ludovici, G
De Marchis, ML
Grenga, I
Schirru, M
Guadagni, F
Roselli, M

February 2011

The aim of this study is to evaluate the influence of germline vascular endothelial growth factor (V...

Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study

Hein, Alexander
Lambrechts, Diether
von Minckwitz, Gunter
Haeberle, Lothar
Eidtmann, Holger
Tesch, Hans
Untch, Michael
Hilfrich, Joern
Schem, Christian
Rezai, Mahdi
Gerber, Bernd
Costa, Serban Dan
Blohmer, Jens-Uwe
Schwedler, Kathrin
Kittel, Kornelia
Fehm, Tanja
Kunz, Georg
Beckmann, Matthias W
Ekici, Arif B
Hanusch, Claus
Huober, Jens
Liedtke, Cornelia
Mau, Christine
Moisse, Matthieu
Mueller, Volkmar
Nekljudova, Valentina
Peuteman, Gilian
Rack, Brigitte
Rubner, Matthias
Van Brussel, Thomas
Wang, Liewei
Weinshilboum, Richard M
Loibl, Sibylle
Fasching, Peter A

December 2015

Studies assessing the effect of bevacizumab (BEV) on breast cancer (BC) outcome have shown different...

Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

LOUPAKIS F
RUZZO, ANNAMARIA
SALVATORE L
CREMOLINI C
MASI G
FRUMENTO P
SCHIRRIPA, M
CATALANO V
GALLUCCIO N
CANESTRARI E
VINCENZI B
SANTINI D
BENCARDINO K
RICCI V
MANZONI M
DANOVA M
TONINI G
MAGNANI, MAURO
FALCONE A
GRAZIANO F.

January 2011

Background: Molecular predictors of bevacizumab efficacy in colorectal cancer have not been identifi...

Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab

Fotios Loupakis (430779)
Chiara Cremolini (430780)
Dongyun Yang (430781)
Lisa Salvatore (430782)
Wu Zhang (220174)
Takeru Wakatsuki (430783)
Pierre Bohanes (430784)
Marta Schirripa (430785)
Leonor Benhaim (430786)
Sara Lonardi (430787)
Carlotta Antoniotti (430788)
Giuseppe Aprile (89417)
Francesco Graziano (430789)
Annamaria Ruzzo (430790)
Sara Lucchesi (430791)
Monica Ronzoni (430792)
Ferdinando De Vita (337845)
Giuseppe Tonini (222938)
Alfredo Falcone (121178)
Heinz-Josef Lenz (430793)

July 2013

<div>PurposeThe potential impact of different SNPs of VEGF/VEGFR pathway on the cli...

Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients.

Issam Makhoul
Valentina K Todorova
Eric R Siegel
Stephen W Erickson
Ishwori Dhakal
Vinay R Raj
Jeannette Y Lee
Mohammed S Orloff
Robert J Griffin
Ronda S Henry-Tillman
Suzanne Klimberg
Laura F Hutchins
Susan A Kadlubar

January 2017

We previously reported improved pathologic complete response (pCR) in a prospective phase II study u...

Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100

Schneider, B. P.
Li, L.
Shen, F.
Miller, K. D.
Radovich, M.
O'Neill, A.
Gray, R. J.
Lane, D.
Flockhart, D. A.
Jiang, G.
Wang, Z.
Lai, D.
Koller, D.
Pratt, J. H.
Dang, C. T.
Northfelt, D.
Perez, E. A.
Shenkier, T.
Cobleigh, M.
Smith, M. L.
Railey, E.
Partridge, A.
Gralow, J.
Sparano, J.
Davidson, N. E.
Foroud, T.
Sledge, G. W.

September 2014

Background: Bevacizumab has broad anti-tumour activity, but substantial risk of hypertension. No rel...

VEGF GENE POLYMORPHISMS IN THE PREDICTION OF BENEFIT FROM FIRST-LINE FOLFIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)

Loupakis, F
Ruzzo, Annamaria
Salvatore, L
Canestrari, E
Cremolini, C
Masi, G
Schirripa, M
Spoto, C
Galluccio, N
Vincenzi, B
Santini, D
Bencardino, K
Ricci, V
Catalano, V
Manzoni, M
Danova, M
Tonini, G
Magnani, Mauro
Falcone, A
Graziano, F.

January 2009

Introduction: Addition of BV to first-line irinotecan plus 5FU improves PFS and OS of mCRC pts. Mea...

Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy

Abstract

Extracted data

Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy

Abstract

Extracted data

Related items

Related items